In vitro diagnosis of Top10 or further deepening market monopoly, how can domestic IVD companies redeem?

Release date: 2015-09-16

EvaluateMedTech forecasts based on statistics from 120 companies in the industry: By 2018, global medical technology (including medical devices, diagnostic products) will reach $440 billion in sales, a growth rate of 4.4%. The segment with the largest market share is IVD, which is expected to account for 12.4% of the entire market in 2018, reaching $54.5 billion.

Statistics show that by 2018, the total sales of these ten giants will reach 44.5 billion US dollars, with an average growth rate of 5%. Total sales accounted for 81.6% of the total market share, accounting for 4% higher than the 2011 statistics.

1. Data interpretation

The market potential is unlimited, and the rapid development of the IVD industry is currently the most dynamic sub-sector in China's medical device industry, but its international competition is extremely fierce. From the above table data, it can be seen:

First, the top ten IVD giants in the world account for nine seats in Europe and the United States, while the United States has six seats.

Among the top ten global giants, there are six in the United States; one in Germany; one in France; one in Switzerland; one in Japan. Basically, they are all countries with strong economic and manufacturing industries. Compared with Chinese IVD companies, these ten giant companies also have a long history of development and products, market accumulation, in the industry is a technology-leading, comprehensive product, occupying a very obvious first in the market competition Advantage.

Second, the market share of the top ten enterprises has gradually increased, and the market monopoly has deepened.

Relying on its advanced technology and comprehensive products and brand inheritance, the top ten giants take the lead in seizing the market opportunities, and at the same time continue to expand themselves and dominate the world market through mergers and acquisitions. The data for 2011 shows that the total sales of ten companies accounted for 77.6%, and it is expected to grow at an average growth rate of 5%. By 2018, the total sales share will further climb to 81.6%, and ten companies will occupy the entire Eighty percent of the market - the entire IVD market will enter the era of monopoly.

The third is: "One super and many strong" situation

Roche, which ranks first, has nearly 20% of the global market share with nearly $10 billion in sales, showing Roche's strong dominance in the IVD field; Danaher (Beckman Coulter), Siemens, Abbott The market share of about 10% has become the top three after Roche, and the remaining six companies have a share of less than 10%.

2. Domestic IVD industry analysis

At present, although the domestic IVD enterprises have tremendous growth in quantity, scale and technology, the market occupancy rate has also made great progress, but the imported IVD reagents still occupy a large market in the domestic market, especially the top three hospitals. Domestic brands still face fierce competition.

There are many domestic IVD companies, but they have not formed a size comparable to the top ten giants. Although some enterprises have reached or even lead foreign giants in technology, they have far-reaching differences in product richness and brand establishment. It is also impossible to compare with promotion.

Although the domestic IVD field is very hot, technology and capital inflows are very large, but most of the enterprises are still in the stage of “small play” and cannot be gathered into a scale. In terms of brand establishment, the domestic reputation is not high, but it is not international. The law is against these giant companies.

The reality gap is that domestic IVD companies have missed the first-mover advantage of gold development, and how to maximize the advantage of latecomer has become the most concerned issue in the industry.

Under the premise of mastering advanced technology, how to form a competitive company with a large amount of products and large quantities, which requires policy, capital, technology, talents and other multi-faceted resources, perhaps in the image industry Will give some inspiration to the IVD field. In short, there is still a long way to go in the development of the domestic IVD industry.

Source: Bio-Exploration

Fresh Single Packed Sweet Corn

Jilin Province Agricultural Sister-in-law Food Co., Ltd. was established in 2012 and has been in the export business since 2012. We mainly export to 16 countries all over the world.

About our main product - Corn

Corn is a kind of food that is often encountered in daily life, and it is also a kind of food to supplement the diet. Its edible benefits are as follows:
1. The fiber content of a cup of corn is 18.4% of the recommended daily amount. This helps reduce digestive problems such as constipation and hemorrhoids.

2. Corn is rich in minerals, which are beneficial to the human body in many ways.
3. Corn is a rich source of calories and is the main food in the diet of many people. The caloric content of corn is 342 calories per 100 grams, which is the highest among grains.

4. The health benefits of corn include controlling diabetes, preventing heart disease, and reducing high blood pressure.

5. Contain a lot of vitamin B group, vitamin B is called happiness factor in medicine, so eating corn can improve depression.
6. Corn not only provides necessary calories for healthy daily metabolism, but also a rich source of vitamin A, vitamin E and many minerals

If you have any questions, please contact us directly. If you have any questions, please email us directly.

Sweet Corn Cob,Yellow Sweet Corn,Sweet Corn,Fresh Corn On Cob

Jilin Province Argricultural Sister-in-law Food Co., Ltd. , https://www.nongsaocorns.com